Edimer raises $18m to develop ultra-rare disease therapy
This article was originally published in Scrip
Biotechnology firm Edimer Pharmaceuticals has raised $18m in series B financing –with input from Sanofi-Genzyme venture capital firm – to continue development of its novel therapy treating rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED).
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.